Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies

Transaction provides potential for further development of novel mAbs while allowing Arsanis to continue to focus its resources on ongoing Phase 2 clinical trial of lead product candidate ASN100

April 4, 2018
Arsanis Biosciences GmbH

WALTHAM, Mass. & VIENNA--(BUSINESS WIRE)--Apr. 4, 2018-- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that it has entered into an agreement under which BB100, LLC has secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license, to monoclonal antibodies (mAbs) targeting E. coli that were discovered by Arsanis in its ASN200 program.

 

Full Press Release available here